Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IO Biotech Inc IOBT

Healthcare Biotechnology
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the... see more

Recent & Breaking News (NDAQ:IOBT)

IO Biotech Announces Second Quarter Results for 2022

GlobeNewswire August 11, 2022

IO Biotech to Participate in the 2022 BIO International Convention

GlobeNewswire June 6, 2022

IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022

GlobeNewswire May 26, 2022

IO Biotech to Participate in the Jefferies Healthcare Conference

GlobeNewswire May 23, 2022

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

GlobeNewswire May 18, 2022

IO Biotech Announces First Quarter Results for 2022

GlobeNewswire May 16, 2022

IO Biotech Hosting Key Opinion Leader Webinar Series

GlobeNewswire April 22, 2022

IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

GlobeNewswire April 12, 2022

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

GlobeNewswire April 8, 2022

IO Biotech Announces Year-End Results for 2021

GlobeNewswire March 31, 2022

IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022

GlobeNewswire March 8, 2022

IO Biotech to Present at 42nd Annual Cowen Healthcare Conference

GlobeNewswire March 4, 2022

IO Biotech Announces Appointment of David V. Smith to its Board of Directors

GlobeNewswire March 3, 2022

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

GlobeNewswire December 9, 2021

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

GlobeNewswire December 6, 2021

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire November 9, 2021

IO Biotech, Inc. Announces Pricing of Initial Public Offering

GlobeNewswire November 4, 2021